1. Systemic Injections of Cannabidiol Enhance Acetylcholine Levels from Basal Forebrain in Rats.
- Author
-
Murillo-Rodríguez E, Arankowsky-Sandoval G, Rocha NB, Peniche-Amante R, Veras AB, Machado S, and Budde H
- Subjects
- Animals, Cannabidiol administration & dosage, Male, Rats, Wistar, Time Factors, Wakefulness drug effects, Wakefulness-Promoting Agents administration & dosage, Wakefulness-Promoting Agents pharmacology, Acetylcholine metabolism, Basal Forebrain drug effects, Cannabidiol pharmacology
- Abstract
Cannabis sativa is a plant that contains more than 500 components, of which the most studied are Δ
9 -tetrahydrocannabinol (Δ9 -THC) and cannabidiol (CBD). Several studies have indicated that CBD displays neurobiological effects, including wake promotion. Moreover, experimental evidence has shown that injections of CBD enhance wake-related compounds, such as monoamines (dopamine, serotonin, epinephrine, and norepinephrine). However, no clear evidence is available regarding the effects of CBD on additional wake-related neurochemicals such as acetylcholine (ACh). Here, we demonstrate that systemic injections of CBD (0, 5, 10 or 30 mg/kg, i.p.) at the beginning of the lights-on period, increase the extracellular levels of ACh collected from the basal forebrain and measured by microdialysis and HPLC means. Moreover, the time course effects on the contents of ACh were present 5 h post-injection of CBD. Altogether, these data demonstrate that CBD increases ACh levels in a brain region related to wake control. This study is the first to show the effects of ACh levels in CBD-treated rats and suggests that the basal forebrain might be a site of action of CBD for wakefulness modulation.- Published
- 2018
- Full Text
- View/download PDF